Influence of inhalation device on asthmatic patients quality of life: Switch MDI to Turbuhaler;Influence du dispositif d'inhalation sur la qualite de vie des patients asthmatiques: Substitution des aerosols doseurs habituels par le Turbuhaler®

Allergie et Immunologie

Volumn 28, Issue 6, 1996, Pages 202-217

  Rocca Serra, J P ^a   Malka, M ^b   Caekert, A ^b   Marty, M ^c  

^a HÔPITAL SAINT JOSEPH   (France)

^b Laboratoires Astra France   (France)

^c Clinica Et Statistica   (France)

Author keywords

asthma; inhaled steroids; MDI; quality of life; Turbuhaler

Indexed keywords

BUDESONIDE; CORTICOSTEROID; TERBUTALINE;

ADULT; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL;

EID: 0029956313     PISSN: 03979148     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. JAESCHKE R, GUYATT GH. In : Spilker, editors. How to develop and validate a new quality of life instrument, in quality of life assessments in clinical trials. New York: Raven Press Ltd 1990.
2. SELROOS O, BACKMAN R, FORSEN KO, LOFROSS AB, NIEMISTO M, PIETINALHO A, RISKA H. Etude comparative de l'efficacité clinique de budésonide en Turbuhaler® et du dipropionate de béclométhasone en aérosol-doseur avec chambre d'inhalation volumatic. Allergy 1994 ; 49:833-836.
3. SELROOS O, BACKMAN R, FORSEN KO, LOFROSS AB, NIEMISTO M, PIETINALHO A, fIKfS C, RISKA H. Effets secondaires des corticoïdes inhalés : comparaison aérosol-doseurs pressurisés et Turbuhaler® lors d'un traitement de 4 ans. Allergy 1994 , 49:888-890.
4. BRAMBILLA C, GODARD P, LACRONIQUE J, ALLAERT FA, DUROUX P, et le Groupe Français d'Essai du Budésonide. Etude comparative de réduction des doses sur 3 mois de dipropionate de béclométhasone et de budésonide dans le traitement de l'asthme modéré à sévère de l'adulte. Drug Invest 1994 ; 8:49-56.
5. MALKA M. Intérêt des dispositifs d'inhalation à poudre dans le traitement de l'asthme. Rev Méd Interne 1994 ; 15:254s-255s.
6. HAAHTELA T, JARVINEN M, KAVA T, KIVIRANTA K, KOSKINEN S, LEHTONEN K et al. Effets de la réduction ou de l'interruption du budésonide en inhalation chez des patients présentant un asthme léger. N Eng J Med 1994 ; 331:700-706
7. JONES AH, LANGDON CG, LEE PS, LINGHAM SA, NANKANT JP, FOLLOWS RMA et al. Pulmicort® Turbuhaler® once daily as initial prophylactic therapy for asthma. Respir Med 1994 ; 88:293-299.
8. PETRIE GR, CHOO-KANG YFJ, CLARK RA, MILLEDGE JS, STUDDY PR, WHITFIELD RJ et al. An assessment of the Acceptability of Two Breath-Actuated Corticosteroïd Inhalers: Comparison of Turbuhaler® with Diskhalers®. Drug Invest 1990 ; 2:129-131.
9. QUIRK FH, JONES PW. Patients' perception of distress due to symptoms and effects of asthma on daily living and an investigation of possible influential factors. Clin Sci 1990 ; 79:17-21.
10. QUIRK FH, BAVEYSTOCK CM, WILSON R, KONES PW. Influence of demographic and disease related factors on the degree of distress associated with symptoms and restriction on daily living due to asthma in six countries. Eur Resp J 1991 ; 4:167-171.
11. JONES PW, QUIRK FH, BAVEYSTOCK CM, little johns P. A self complete measure of health status for chronic airflow limitation. Ann Rev Pers Dis 1992 ; 145:1321-1327.
12. DAVIS R, Mc TAVISH D. Budesonide : An Appraisal of the Basis of its Pharmacoeconomic and Quality-of-Life Benefits in Asthma. Pharmacoeconomics 1995 ; 7:457-470.
13. GUYATT GH, VELDHUYZZEN VAN ZANTEN, FEENY D, PATRICK DL. Measuring quality of life in clinical trials a taxonomy and review. CMAJ 1989 ; 140:1441-1448.
14. TUGWELL P, BOMBARDIER C. A methodologic Framework for developing and selecting Endpoints in clinical trials. J Rheumatol 1982 ; 9:758-762.
15. JONES PW. Issues Concerning Health-Related Quality of Life in COPD. Chest 1995 , 187s-191s.
16. BERGNER M, BARBITT RA, POLLARO WE. The Sickness Impact Profile : validation of a health status measure. Med Care 1976 ; 14:57-67.
17. KAPLAN RM, BUSH JW, BERRY CC. Types of validity for an index of well-being. Health Ser Res 1976 ; 11:478-507.
18. STEWART AL, GREENFIELD S, HAYS RD, et al. Functional status and well-being of patients with chronic conditions. Results from the Medical Outcome Study. JAMA 1989 ; 262:907-913.
19. GUYATT GH, BERMAN LB, TOWNSEND M, PUGSLEY SO, CHAMBERS LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987a ; 42:773-778.
20. HYLAND ME, FINNIS S, IRVINE SH A scale for assessing quality of life in adult asthma sufferers. J Psych Res 1991 ; 35:99-110.
21. JONES PW and the Nedocromil Sodium Quality of Life Study Group. Quality of life, symptoms and pulmonary function in asthma : long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Eur Respir J 1994 ; 7:55-62.
22. JUNIPER EF, GUYATT GH, EPSTEIN RS, FERRIE PJ, JAESCHKE R, HILLER TK. Evaluation of impairment of health related quality of life in asthma : development of a questionnaire for use in clinical trials. Thorax 1992 ; 47:76-83.
23. HYLAND ME, CROCKER GR. Validation of an asthma quality of life diary in a clinical trial. Thorax 1995 ; 50:724-730.
24. GAY AL, RICHARDSON PDI, HOWARTH NJ. The influence of budesonide (Pulmicort) on patients' lifestyles in the management of asthma. Clin trials J 1989 ; 26:175-80.
25. CAMPBELL LM, WATSON DG, VENABLES TL, et al. Once daily budesonide Turbohaler® compared with placebo as initial prophylactic therapy for asthma. Br J Clin Res 1991 , 2:111-22.
26. NANKANI JN, NORTHFIELD M, BERAN YM, RICHARDSON PDI. Changes in asthmatic patients' symptoms and lifestyles on institutions of inhaled budesonide therapy. Curr Med Resp Opin 1990 ; 12:198-206.